top of page
Loges.jpg

Prof. Dr. Sonja Loges

(Associated Member since April, 2021)    Project AP

​

​

Department of Personalized Oncology

Medical Faculty Mannheim, Heidelberg University

Sonja.Loges(at)medma.uni-heidelberg.de

Professional Career

Since 2021

Scientific Director

Mannheim Cancer Center, Mannheim, Germany

Since 2020

Head of Division

Personalized Medical Oncology

German Cancer Research Center (DKFZ), Heidelberg, Germany

Since 2020

Full Professor (W3)

Medical Faculty Mannheim (CBTM), Heidelberg University, and Chair of the Depatment of Personalized Oncology, University Hospital Mannheim

2016 -2020

Heisenberg Professor (W3)

Department of Hematology and Oncology

University Medical Center, Hamburg, Germany

2015 - 2020

Leader of Thoracic Oncology

and Personalized Oncology Programs, Department of Hematology and Oncology, University Medical Center Hamburg

2015 - 2020

Attending Physician and Group Leader

Department of Hematology/Oncology and Institute of Tumor Biology

University Medical Center, Hamburg, Germany

2010 - 2015

Junior Group Leader

Department of Hematology and Oncology, Insitute of Tumor Biology University Medical Center Hamburg

2007 -2010

Post-doctoral Researcher

VIB-KU Leuven, Belgium

2005

Dr. med.

University Medical Center Hamburg

2000 - 2004

Ph.D.

in Biochemistry and in Biochemistry and Molecular Biology

Department of Biology, University of Hamburg

Selected Publications

Selected publications

​

Janning M, Süptitz J, Albers-Leischner C, Delpy P, Tufman A, Velthaus-Rusik JL, Reck M, Jung A, Kauffmann-Guerrero D, Bonzheim I, Brändlein S, Hummel HD, Wiesweg M, Schildhaus HU, Stratmann JA, Sebastian M, Alt J, Buth J, Esposito I, Berger J, Tögel L, Saalfeld FC, Wermke M, Merkelbach-Bruse S, Hillmer AM, Klauschen F, Bokemeyer C, Buettner R, Wolf J, Loges S: Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). Ann Oncol. S0923-7534, 2022.

​

Carmeliet P, Li X, Treps L, Conradi LC, Loges S: RAISEing VEGF-D's importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients. Ann Oncol. 29:527-529, 2018.

​

Bauer R*, Udonta F*, Wroblewski M, Ben-Batalla I, Santos IM, Taverna F, Kuhlencord M, Gensch V, Päsler S, Vinckier S, Brandner JM, Pantel K, Bokemeyer C, Vogl T, Roth J, Carmeliet P, Loges S: Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of antiangiogenic therapy. Cancer Res. 78:3220-3232, 2018. (*equal contribution)

​

Wroblewski M, Bauer R, Cubas Córdova M, Udonta F, Ben-Batalla I, Legler K, Hauser C, Egberts J, Janning M, Velthaus J, Schulze C, Pantel K, Bokemeyer C, Loges S: Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B. Nat Commun. 8:269, 2017.

​

Waizenegger JS, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab MS, Pantel K, Bokemeyer C, Loges S: Role of growth arrest-specific gene 6-Mer axis in multiple myeloma. Leukemia. 29:696-704, 2015.

​

Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas-Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens JB, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S: Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood. 122:2443-52, 2013.

​

Schmidt T*, Kharabi Masouleh B*, Loges S*, Cauwenberghs S, Fraisl P, Maes C, Jonckx B, De Keersmaecker K, Kleppe M, Tjwa M, Schenk T, Vinckier S, Fragoso R, De Mol M, Beel K, Dias S, Verfaillie C, Clark RE, Brümmendorf TH, Vandenberghe P, Rafii S, Holyoake T, Hochhaus A, Cools J, Karin M, Carmeliet G, Dewerchin M, Carmeliet P.: Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. Cancer Cell. 19:740-53, 2011. (*equal contribution)

​

Loges S*, Schmidt T*, Tjwa M, van Geyte K, Lievens D, Lutgens E, Vanhoutte D, Borgel D, Plaisance S, Hoylaerts M, Luttun A, Dewerchin M, Jonckx B, Carmeliet P: Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood. 115:2264-73, 2010. (*equal contribution)

​

Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, Loges S, Albrecht I, Jonckx B, Vinckier S, Van Steenkiste C, Tugues S, Rolny C, De Mol M, Dettori D, Hainaud P, Coenegrachts L, Contreres JO, Van Bergen T, Cuervo H, Xiao WH, Le Henaff C, Buysschaert I, Kharabi Masouleh B, Geerts A, Schomber T, Bonnin P, Lambert V, Haustraete J, Zacchigna S, Rakic JM, Jiménez W, Noël A, Giacca M, Colle I, Foidart JM, Tobelem G, Morales-Ruiz M, Vilar J, Maxwell P, Vinores SA, Carmeliet G, Dewerchin M, Claesson-Welsh L, Dupuy E, Van Vlierberghe H, Christofori G, Mazzone M, Detmar M, Collen D, Carmeliet P: Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell. 141:178-90, 2010.

 

Loges S, Heil G, Bruweleit M, Schoder V, Butzal M, Fischer U, Gehling M, Schuch G, Hossfeld DK, Fiedler W:. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol. 23:1109-17, 2005.

bottom of page